SUPERNUS PHARMACEUTICALS, INC. Quarterly Costs and Expenses in USD from Q1 2011 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Supernus Pharmaceuticals, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2011 to Q3 2024.
  • Supernus Pharmaceuticals, Inc. Costs and Expenses for the quarter ending September 30, 2024 was $135M, a 7.48% decline year-over-year.
  • Supernus Pharmaceuticals, Inc. annual Costs and Expenses for 2022 was $621M, a 25.8% increase from 2021.
  • Supernus Pharmaceuticals, Inc. annual Costs and Expenses for 2021 was $494M, a 42.4% increase from 2020.
  • Supernus Pharmaceuticals, Inc. annual Costs and Expenses for 2020 was $347M, a 42% increase from 2019.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $135M -$10.9M -7.48% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-04
Q2 2024 $146M -$7.39M -4.83% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $147M -$1.79M -1.21% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q3 2023 $580M $146M -$33.1M -18.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-04
Q2 2023 $614M $153M -$5.56M -3.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $619M $149M -$1.95M -1.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $621M $133M -$20M -13% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-09
Q3 2022 $641M $179M +$63M +54.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $578M $159M +$51.5M +48% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $527M $151M +$32.8M +27.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $494M $153M +$52.4M +52.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $441M $116M +$16.9M +17% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $424M $107M +$26M +32.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $398M $118M +$51.8M +78.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $347M $101M +$40.9M +68.6% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-09
Q3 2020 $306M $99M +$36.6M +58.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 $269M $81.2M +$19.1M +30.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 $250M $66M +$5.92M +9.86% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $244M $59.6M -$16.4M -21.6% Oct 1, 2019 Dec 31, 2019 10-K 2020-02-28
Q3 2019 $261M $62.4M -$3.11M -4.75% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $264M $62.1M -$1.72M -2.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-17
Q1 2019 $265M $60M +$1.01M +1.71% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 $264M $76.1M +$22M +40.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-28
Q3 2018 $242M $65.5M +$7.47M +12.9% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-28
Q2 2018 $235M $63.8M +$14.1M +28.2% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-28
Q1 2018 $221M $59M +$18.2M +44.7% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-28
Q4 2017 $203M $54.1M +$8.01M +17.4% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-01
Q3 2017 $195M $58.1M +$21.1M +57% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-01
Q2 2017 $174M $49.8M +$9.78M +24.5% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-01
Q1 2017 $164M $40.8M +$3.03M +8.03% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-01
Q4 2016 $161M $46.1M +$10.3M +28.7% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 $151M $37M +$2.69M +7.86% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 $148M $40M +$8.15M +25.6% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 $140M $37.8M +$13.1M +52.8% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
Q4 2015 $127M $35.8M +$9.7M +37.1% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-16
Q3 2015 $117M $34.3M +$10.9M +46.3% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-16
Q2 2015 $106M $31.8M +$5.92M +22.8% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-16
Q1 2015 $100M $24.7M +$2.2M +9.78% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-16
Q4 2014 $98M $26.1M +$4.42M +20.4% Oct 1, 2014 Dec 31, 2014 10-K/A 2017-01-20
Q3 2014 $93.5M $23.4M +$4.99M +27.1% Jul 1, 2014 Sep 30, 2014 10-K/A 2017-01-20
Q2 2014 $88.5M $25.9M +$10.2M +64.5% Apr 1, 2014 Jun 30, 2014 10-K/A 2017-01-20
Q1 2014 $78.4M $22.5M +$4.45M +24.6% Jan 1, 2014 Mar 31, 2014 10-K/A 2017-01-20
Q4 2013 $73.9M $21.7M +$7.86M +56.8% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-12
Q3 2013 $66.1M $18.4M +$6.05M +48.9% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-12
Q2 2013 $60M $15.8M +$6.41M +68.6% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-12
Q1 2013 $53.6M $18.1M +$9.97M +123% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-12
Q4 2012 $43.6M $13.8M +$3.55M +34.5% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-21
Q3 2012 $40.1M $12.4M +$2.46M +24.7% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-21
Q2 2012 $37.6M $9.35M +$202K +2.21% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-21
Q1 2012 $37.4M $8.09M -$1.11M -12.1% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-21
Q4 2011 $38.6M $10.3M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-15
Q3 2011 $9.93M Jul 1, 2011 Sep 30, 2011 10-K 2013-03-15
Q2 2011 $9.15M Apr 1, 2011 Jun 30, 2011 10-K 2013-03-15
Q1 2011 $9.2M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.